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SUMMARY
 BACKGROUND—The Uganda Prisons Service (UPS) is responsible for the health of 
approximately 32 500 inmates in 233 prisons. In 2008 a rapid UPS assessment estimated TB 
prevalence at 654/100 000, three times that of the general population (183/100 000). Although 
treatment programs exist, little is known about treatment completion in sub-Saharan African 
prisons.
 METHODS—We conducted a retrospective study of Ugandan prisoners diagnosed with TB 
from June 2011 to November 2012. We analyzed TB diagnosis, TB-HIV comorbidity and 
treatment completion from national registers and tracked prison transfers and releases.
 RESULTS—A total of 469 prisoners were diagnosed with TB over the 1.5-year period 
(incidence 955/100 000 person-years). Of 466 prisoners starting treatment, 48% completed 
treatment, 43% defaulted, 5% died and 4% were currently on treatment. During treatment, 12% of 
prisoners remaining in the same prison defaulted, 53% of transfers defaulted and 81% of those 
released were lost to follow-up. The odds of defaulting were 8.36 times greater among prisoners 
who were transferred during treatment.
 CONCLUSIONS—TB incidence and treatment default are high among Ugandan prisoners. 
Strategies to improve treatment completion and prevent multidrug resistance could include 
avoiding transfer of TB patients, improving communications between prisons to ensure treatment 
follow-up after transfer and facilitating transfer to community clinics for released prisoners.
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TUBERCULOSIS (TB) remains a persistent global health problem. While some countries 
are making progress towards the Millennium Development Goal of reversing the overall 
Correspondence to: Amee Schwitters, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, Mailstop E-30, Atlanta, GA 30329-1902, USA. Tel: (+1) 404 718 8583. Fax: (+1) 404 718 8583. efn6@cdc.gov. 
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of 
the CDC.
Conflict of interest: none declared.
HHS Public Access
Author manuscript
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2016 June 27.
Published in final edited form as:













rates and numbers of TB by 2015, progress remains limited in other countries.1 More than 
80% of the world’s TB cases are found in 22 countries, with 40% of cases in China and 
India alone.1 Although it contains only 11% of the world’s population, the African continent 
makes up 24% of global TB cases and 34% of TB-related deaths.1,2 The high occurrence of 
TB continues to be driven by the ongoing human immunodeficiency virus (HIV) epidemic, 
weak health care systems and a lack of laboratories.3
TB disease is estimated to be the leading cause of death of prisoners worldwide.4 TB is also 
more prevalent among prisoners than among the general population in most countries,5–7 
with a worldwide incidence in prisons 20 times higher than in the general population.8,9 
According to a 2008 rapid situation assessment in Ugandan prisons, TB prevalence among 
prisoners was 654 per 100 000 population,10 three and a half times the prevalence estimate 
in the general Ugandan population of 183/100 000.11 Overcrowding, poor hygiene and diet, 
indoor confinement and limited access to health care leave prisoners at increased risk for TB 
and HIV.8,12 Multidrug-resistant TB (MDR-TB) is identified more frequently in prisoners 
and prison staff, and remains an emerging threat to national TB programs.13–17
In sub-Saharan Africa, TB remains one of the fastest growing epidemics in prison 
populations,10,18,19 while HIV prevalence among prisoners is estimated to be 2–50 times 
that among non-prison populations.8 In Uganda, HIV prevalence among prison inmates is 
estimated at 11% among males and 13% among females, one and a half times the national 
prevalence of 7.3%.10
The Uganda Prisons Service (UPS) is responsible for the welfare, health and security of both 
prison inmates and staff. The UPS is divided into 14 administrative regions and manages 233 
prisons countrywide, of which 63 have health units, while the remaining prisons use public 
health facilities operated by the Ministry of Health (MOH) in neighboring communities. 
Prisoners diagnosed with TB are transferred to one of 10 TB treatment administering 
regional centers for initiation of anti-tuberculosis treatment.
The average Ugandan prison population during our study period was 32 724, with male 
prisoners comprising 96% of the prison population. Remand prisoners awaiting trial 
comprise approximately 55% of the prison population. Annual turnover is estimated at 
approximately 100 000 inmates. With the high turnover of prisoners, the risk of TB 
transmission both within prisons and to community members is a matter of concern. TB 
screening is offered at entry into prison, and annually at larger prison health units under a 
mass TB screening program. HIV testing strategies include both voluntary counseling and 
testing and provider-initiated HIV counseling and testing. Both TB and HIV treatment are 
available to prisoners through the prison health system.
In the present study, we sought to determine TB incidence among Ugandan prison inmates, 
and to analyze TB treatment outcomes and risk factors for treatment default to assist the 
UPS in strengthening TB surveillance, treatment and referral systems.
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We calculated person-years (py) of TB incidence using recorded TB cases in the registers. 
Ugandan health facilities, including prison health facilities, utilize the national Health 
Management Information System (HMIS) registers to track various patient outcomes, 
including HIV and TB. We collected HMIS unit TB registers from each of the 10 regional 
Uganda prison health centers offering anti-tuberculosis treatment. All patients were 
prisoners aged ≥18 years diagnosed with TB between June 2011 and November 2012, and 
had a TB treatment outcome recorded by June 2013, the last treatment month for those 
initiating treatment in November 2012. All prisoners with a TB diagnosis recorded in the 
HMIS TB register during the above time period were included in the analysis. Duplicate 
patient entries were removed before analysis.
Seven variables were collected from the registers and analyzed: sex, age, disease class, case 
definition, transfer/release status, sputum examination results, and treatment outcomes. The 
HMIS registers use standard Uganda MOH TB case definitions and treatment outcomes 
adopted from the World Health Organization (WHO) which are outlined in the National 
Tuberculosis and Leprosy Program guidelines.20 However, prison staff do not consistently 
distinguish between ‘cured’ and ‘treatment completed’ when assigning treatment outcomes, 
instead often defining all successful treatment outcomes as ‘treatment completed’. To 
account for this, we chose to use the standard WHO outcome, ‘treatment success,’ defined 
as ‘a sum of cured and completed treatment’ (Table 1).21 Furthermore, HMIS registers list 
‘prison transfer’ as a treatment outcome. As we were able to track transferred inmates 
between prisons, we defined ‘prison transfer’ as a prisoner transferring prison locations, and 
‘released’ for those prisoners released from the prison system while still on anti-tuberculosis 
treatment.
Extracted data were entered into Epi-Info (Centers for Disease Control and Prevention 
[CDC], Atlanta, GA, USA) and analyzed using SAS 9.3 (Statistical Analysis Software 
Institute, Cary, NC, USA). We conducted bivariate and multivariate logistic regression 
analyses to determine associations with treatment default within the prison system. All 
variables collected were entered into the multivariate analysis, and adjusted odds ratios 
(aORs) and 95% confidence intervals (CIs) are presented for default treatment outcomes.
Ethical approval for this study was obtained from the CDC, the Uganda Virus Research 
Institute, Entebbe, and the Uganda National Council of Science & Technology, Kampala, 
Uganda.
 RESULTS
A total of 469 TB cases were recorded among prisoners in the HMIS registers in UPS 
facilities between June 2011 and November 2012, resulting in an observed incidence rate of 
955/100 000 py. Males, who comprised 98% (n=460) of the population, had a higher 
incidence rate (976/100 000) than females (452/100 000). Although more than half of 
patients (57%) were co-infected with HIV, only 176 (66%) were on antiretroviral therapy 
(ART) (Table 2).
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Almost all of the 469 TB diagnosed patients (91%) (n = 424) were newly diagnosed (Table 
2); 18% had extra-pulmonary TB. Similar proportions of HIV-positive and HIV-negative TB 
patients were sputum smear-negative. No statistically significant demographic differences in 
treatment outcomes were found. Of 466 prisoners starting anti-tuberculosis treatment, 48% 
(n=222) achieved treatment success, 43% (n =202) defaulted, 5% (n =22) died, 4% (n = 18) 
were still on treatment and 0.4% (n = 2) had treatment failure as of June 2013 (Table 2). 
Among the 466 starting treatment, 199 remained in the same prison throughout their anti-
tuberculosis treatment, 137 prisoners transferred prison locations during treatment and 130 
prisoners were released during treatment. During treatment, 12% of the 199 prisoners 
remaining in the same prison defaulted, whereas 53% of the 137 prisoners who were 
transferred defaulted. Among those defaulting while in prison, 77% defaulted after transfer. 
Of the 130 prisoners released during treatment, 81% (n = 105) were lost to follow-up and 
were considered to have defaulted by UPS health staff.
In multivariate analysis, the odds of anti-tuberculosis treatment default were 8.4 times 
greater (aOR 8.36, 95%CI 4.69–14.91) among transferred prisoners than among prisoners 
who were not transferred during treatment (Table 3). There was no evidence of association 
between default and sex, age, HIV status and disease class.
 DISCUSSION
The results of our analysis show that TB incidence among Ugandan prisoners is five-fold 
higher than in the general population, with TB incidence among males more than twice that 
among females. Treatment default is high among prisoners transferred during the course of 
their treatment, and the vast majority of prisoners released during anti-tuberculosis treatment 
are lost to follow-up.
Screening new prison inmates and periodic screening of prisoners and staff enables early 
detection of TB22,23 and reduces TB among prison populations.24 Although UPS has robust 
programs to screen all incoming prisoners for TB and an annual mass TB screening program 
for high-volume facilities where all inmates and staff are screened, poor rates of treatment 
completion facilitate TB transmission and the development of drug resistance in the prison 
setting.
Co-infection with HIV was high: more than half (58%) of the prisoners diagnosed with TB 
were HIV-positive. HIV infection is a major risk factor for the development of active TB,25 
and it is possible that the high rates of TB within the UPS are driven in part by the high 
prevalence of HIV infection. HIV screening is offered voluntarily on entry into prison, and is 
available routinely at prisons with health units, and through outreach camps to smaller 
facilities. Ugandan laws, which criminalize homosexuality, prevent the distribution of 
condoms to inmates, hampering HIV prevention in prisons.26 Persons living with HIV 
should be screened at least annually for TB, and certainly at every clinical care or treatment 
encounter; prisoners diagnosed with HIV should be screened for TB as soon as possible 
after their diagnosis. Prompt initiation of ART within 8 weeks of TB diagnosis among 
eligible patients co-infected with TB and HIV may reduce the risk of TB transmission as 
well as TB-associated morbidity and mortality.27
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TB treatment success rates are lower (48% vs. 67%) in Ugandan prisons than among the 
general population.11 Among those defaulting from treatment while in prison, the majority 
(77%) did so after prison transfer. Prisoners are transferred within the prison system for one 
of four reasons: security, health, assignment from a reception center, or before release, when 
they are moved close to their home region. The high proportion of defaulters among 
transferred prisoners highlights an urgent need to improve treatment completion rates to 
prevent the development of drug resistance. While the majority of prisoners defaulted after 
transfer, 12% defaulted while remaining in the same prison. Further research should be 
conducted to better understand factors influencing default among these prisoners and actions 
that can be taken by the prison system to address the problem.
There is currently no consistent screening program for multidrug-resistant TB (MDR-TB) in 
Ugandan prisons. Studies have shown that patients who have to be retreated for TB due to 
default or initial treatment failure are more likely to develop drug resistance, and retreatment 
outcomes are generally poor, with higher default rates.25,28,29 MDR-TB has been shown to 
occur 5–10 times more frequently in previously treated TB patients,30 and mortality is 
higher among MDR-TB patients.11 Drug-resistant TB remains a threat in sub-Saharan 
Africa, where HIV-TB comorbidity remains high and limited resources constrain the ability 
to conduct ongoing TB and anti-tuberculosis drug surveillance.31 In 2011, 1.4% of new TB 
cases and 12% of retreatment TB cases in Uganda were suspected MDR-TB cases.11,32
Strategies to prevent treatment default could include halting prison transfers for inmates on 
anti-tuberculosis treatment except when necessary for security or other health conditions. 
Opportunities exist to strengthen communication, documentation and reporting of prisoners 
on anti-tuberculosis treatment whose transfer is deemed a necessity. For example, ongoing 
medical treatment regimens for TB should be included in prisoner transfer records, including 
a detailed TB treatment completion plan. A treatment completion report should be sent back 
to the regional unit where treatment was initiated to improve tracking and reporting.33 
Improved follow-up, through brief phone calls from the sending TB clinic to the receiving 
clinic, could greatly improve the continuation and completion of TB treatment after prison 
transfer.34
Although default is a highly possible treatment outcome among this group, 81% of prisoners 
released while on anti-tuberculosis treatment were lost to follow-up, preventing knowledge 
and documentation of their treatment outcomes. A continuum of care should be established 
for prisoners nearing release through improved linkage to public clinic facilities.21,33 
Prisoners released while on treatment should, moreover, be given at least 1 week of TB 
drugs to help facilitate adherence.33 Released prisoners could also be presented with the 
option to return to a prison health clinic to finish their anti-tuberculosis treatment.
A cell phone-based system with the provision of airtime to prison health unit staff, and 
directions to update treatment registers a minimum of once per month, including transferees, 
would improve patient tracking and allow better monitoring of treatment outcomes.35
The benefits of TB prevention in prisons extend beyond the prison walls.9,35 Prisoners, 
prison staff and visitors are all at risk for acquiring TB in prisons. Prison staff and visitors, 
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as well as prisoners who default from treatment after release from prison, can transmit TB to 
their family and other contacts in the community.35 Furthermore, community members 
access prison health facilities at some prison locations, putting non-institutionalized persons 
at risk for TB acquisition. The threat of TB transmission from the prison system to the wider 
community can be prevented by aggressively controlling the spread of TB within the prison 
system.
This study has limitations, including those common to retrospective designs (namely 
reliance on historical records and inability to add variables of interest). As registers did not 
differentiate between cure and treatment completion, we were only able to calculate rates for 
these two outcomes combined as treatment success. For the purposes of understanding 
treatment practices and completion in UPS, these data were sufficient. We did not have date 
of entry into the prison system in the TB registers; prisoners who had been in prison for <3 
months may therefore have been included in the analysis. It has been argued that these cases 
should be defined as prevalent cases at entry rather than incident cases in prison.36
Our findings clearly demonstrate that TB is a pressing concern in Ugandan prisons. 
Although TB screening and active case-finding programs exist, the majority of prisoners do 
not complete treatment, due either to prison transfer or loss to follow-up on prison release. 
Strategies to improve treatment completion rates among prisoners through reduced transfers, 
better follow-up when transfer is necessary, and facilitated linkage to public health facilities 
for released prisoners, are critical to prevent TB transmission and the development of drug 
resistance.
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Table 1
Uganda TB treatment outcome definitions
Treatment outcome
Treatment success Sum of cured and completed treatment
Cure TB patient whose sputum smear or culture was positive at the beginning of the treatment but who was smear- or 
culture-negative in the last month of treatment and on at least one previous occasion
Treatment completed TB patient who completed treatment but who does not have a negative sputum smear or culture result in the last month 
of treatment and on at least one previous occasion
Failure TB patient who remains/turns sputum smear- or culture-positive at ≥5 months of anti-tuberculosis treatment
Died TB patient who dies from any cause while still on anti-tuberculosis treatment
Transferred TB patient already registered for anti-tuberculosis treatment in one district/prison who transfers to another prison 
during anti-tuberculosis treatment
Defaulted TB patient who completed >1 month of treatment and interrupted it for ≥2 consecutive months
TB = tuberculosis.
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Table 2
Demographic and TB case characteristics of HIV-positive (n=268) and HIV-negative (n= 192) prisoners 









 18–29 101 (22) 75 (16) 179 (38)
 30–39 111 (24) 58 (12) 172 (37)
 ≥40 53 (11) 48 (10) 102 (22)
 Unknown 3 (1) 11 (2) 16 (3)
Sex
 Male 261 (56) 190 (41) 460 (98)
 Female 7 (1) 2 (.04) 9 (2)
Currently taking cotrimoxazole preventive therapy
 Yes 250 (53) — 254 (54)
 No 9 (2) 192 (4) 197 (42)
 Unknown 9 (2) 0 (0) 18 (4)
Currently on antiretroviral therapy
 Yes 176 (38) — 176 (38)
 No 36 (8) 192 (40) 228 (48)
 Unknown 56 (12) 0 (0) 65 (14)
Disease class
 Sputum smear-positive 98 (21) 101 (22) 203 (43)
 Sputum smear-negative 86 (18) 56 (12) 143 (31)
 Extra-pulmonary 59 (13) 22 (5) 83 (18)
 No sputum detected 23 (5) 13 (3) 38 (8)
 Unknown 2 (0.2) 0 (0) 2 (0.4)
Case definition
 New 246 (53) 172 (37) 424 (91)
 Relapse 12 (3) 4 (1) 17 (4)
 Failure 0 (0) 2 (0.4) 2 (0.4)
 Previous default 8 (2) 13 (3) 23 (5)
 Unknown 2 (0.2) 1 (0.1) 3 (0.5)
TB treatment outcome†
 Success 136 (29) 81 (17) 222 (48)
 Failure 0 (0) 2 (0.4) 2 (0.4)
 Died 17 (4) 5 (1) 22 (5)
 Defaulted 104 (22) 95 (20) 202 (43)
 Ongoing 9 (2) 8 (2) 18 (4)
*
Includes HIV status unknown (n = 9).
†
Three persons diagnosed with TB did not begin treatment.
TB = tuberculosis; HIV = human immunodeficiency virus.
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Table 3
Risk factors for TB treatment default among Ugandan prisoners (n = 466)
Factors Unadjusted OR (95%CI) Adjusted OR (95%CI)
Transferred 8.95 (5.17–15.48) 8.36 (4.69–14.91)
Age, years
 18–29 Reference Reference
 30–39 0.70 (0.45–1.06) 0.66 (0.38–1.16)
 ≥40 0.58 (0.35–0.95) 0.64 (0.35–1.19)
Male 0.94 (0.24–3.53) 1.32 (0.27–6.43)
HIV-positive 0.88 (0.61–1.28) 0.82 (0.50–1.33)
Disease class
 Sputum smear-positive Reference Reference
 Sputum smear-negative 0.62 (0.40–0.96) 0.77 (0.43–1.36)
 Extra-pulmonary 0.69 (0.41–1.17) 0.96 (0.50–1.84)
 No sputum detected 0.76 (0.38–1.54) 1.40 (0.55–3.56)
TB = tuberculosis; OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency virus.
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